While most VF diagnostics rely on reactivity to one antigen alone, typically CF/CTS1, the additional seroreactive proteins identified by NAPPA can potentially be used in conjunction to increase sensitivity and specificity. The gene discussed is TTR; the disease is cystic fibrosis.